Who are Comparator: ProQuad™ (V221)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ProQuad®, MMRV (2006 process), MMRV (AMP).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/comparator-proquad-v221.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Comparator: ProQuad™ (V221) — Competitive Intelligence Brief

Comparator: ProQuad™ (V221) (Comparator: ProQuad™ (V221)) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated combination vaccine. Area: Immunology / Infectious Disease.

phase 3 Live attenuated combination vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Comparator: ProQuad™ (V221) (Comparator: ProQuad™ (V221)) — Merck Sharp & Dohme LLC. ProQuad is a live attenuated combination vaccine that stimulates immune response against measles, mumps, rubella, and varicella viruses.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Comparator: ProQuad™ (V221) TARGET	Comparator: ProQuad™ (V221)	Merck Sharp & Dohme LLC	phase 3	Live attenuated combination vaccine
ProQuad®	ProQuad®	Merck Sharp & Dohme LLC	marketed	Live attenuated combination vaccine
MMRV (2006 process)	MMRV (2006 process)	Merck Sharp & Dohme LLC	phase 3	Live attenuated combination vaccine
MMRV (AMP)	MMRV (AMP)	Merck Sharp & Dohme LLC	phase 3	Live attenuated combination vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated combination vaccine class)

Merck Sharp & Dohme LLC · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Comparator: ProQuad™ (V221) — Competitive Intelligence Brief. https://druglandscape.com/ci/comparator-proquad-v221. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab